morab-202
mAbexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Nov 28, 2017 (NCT03386942)
Timeline
Indications
Mechanism of action
- Folate receptor alphaINHIBITOR
FOLR1 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05577715 | Phase 2 | Nov 30, 2022 | Bristol-Myers Squibb, Eisai |
| NCT05613088 | Phase 2 | Nov 11, 2022 | Bristol-Myers Squibb, Eisai |
| NCT04300556 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2020 | Eisai |
| NCT03386942 | Phase 1 | Nov 28, 2017 | Eisai |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 4 | 2 | 2 | 2017 |
| Bristol-Myers Squibb | For profit | 2 | 2 | 1 | 2022 |
2 organizations
Page 1 / 1